GlassScriptPhysician profile
Matthew Tilton
NPI 1356802649
$1,876.19
in general payments reported to CMS, 2019-2025
36 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $163 · 2023: $604 · 2024: $447 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $259.05 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $228.80 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $174.54 | 2022-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $123.92 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $112.67 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $91.19 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $88.33 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.10 | 2022-2024 | |
| Abbvie INC. | $75.44 | 2022-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $59.06 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $56.10 | 2022-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $42.17 | 2023-2024 | Livalo, Seglentis, Zoryve |
| Sumitomo Pharma America, INC. | $37.84 | 2023 | Gemtesa |
| Collegium Pharmaceutical, INC. | $32.65 | 2025 | Jornay Pm |
| Corium, LLC | $30.98 | 2023 | Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $29.51 | 2024 | Ibsrela |
| Verona Pharma, INC. | $28.58 | 2025 | Ohtuvayre |
| Radius Health, INC. | $26.09 | 2025 | Tymlos |
| Viatris Specialty LLC | $22.53 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $22.52 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.26 | 2023 | Gvoke Hypopen |
| Insulet Corporation | $21.01 | 2025 | Omnipod |
| Medtronic, INC. | $20.49 | 2025 | Minimed 780g |
| Resmed Corp | $19.73 | 2025 | |
| Tandem Diabetes Care, INC. | $17.67 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alkermes, INC. | $16.71 | 2023 | Aristada, Lybalvi |
| Nevro Corp. | $16.57 | 2023 | Senza |
| Otsuka America Pharmaceutical, INC. | $16.00 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $15.62 | 2025 | Shingrix, Arexvy, Bexsero |
| Novartis Pharmaceuticals Corporation | $15.44 | 2025 | |
| Organon LLC | $15.22 | 2025 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $13.85 | 2024 | |
| Exact Sciences Corporation | $13.28 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $12.53 | 2022 | |
| Sobi, INC | $11.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.75 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Tilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.